Düsseldorf, Germany – April 3, 2025 – LenioBio GmbH, a leader in cell free protein expression technologies is now partnering with Avantor, a global life sciences company. This collaboration will make LenioBio’s ALiCE®, a cell-free protein synthesis technology more accessible to researchers across Europe.
ALiCE® allows rapid and efficient production of complex proteins, supporting both early-stage discovery and large-scale production. LenioBio’s innovative solutions will be available through Avantor’s distribution network, ensuring fast, reliable access to tools that accelerate scientific discovery.
“This is another significant milestone, making our ALiCE® technology more accessible and empowering scientists to overcome traditional expression challenges,” said André Goerke, CEO of LenioBio.
Together, LenioBio and Avantor are committed to driving scientific progress and supporting researchers in advancing protein expression.
About LenioBio GmbH
LenioBio GmbH is a life sciences biotech company dedicated to transforming protein production
through its proprietary ALiCE® technology. By eliminating the limitations and bottlenecks of
traditional cell-based systems, LenioBio empowers researchers to explore new frontiers in protein
expression and accelerate the development of cutting-edge therapeutics and diagnostics.